Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy
| Autor: | Yoshino, Takayuki *, Oki, Eiji, Nozawa, Hiroaki, Eguchi-Nakajima, Takako, Taniguchi, Hiroya, Morita, Satoshi, Takenaka, Naruhito, Ozawa, Daisuke, Shirao, Kuniaki |
|---|---|
| Zdroj: | In ESMO Open 2018 3(5) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|